biotech / news / / Ars Technica
Moderna's mRNA-based combination vaccine against both flu and COVID-19 has gotten the green light in Europe.
Europe has authorized Moderna's mRNA-based combination flu and COVID-19 vaccine, mCOMBRIAX.
KEY POINTS
- mCOMBRIAX produces significantly higher immune responses than standard or high-dose flu vaccines.
- Moderna withdrew its US application for mCOMBRIAX and has not yet resubmitted it.
- FDA political appointee Vinay Prasad initially refused to review Moderna's flu vaccine, later reversing the decision.
- The FDA is expected to decide on Moderna's mRNA-1010 flu vaccine by August 5.
COMPANIES
Summarized by Newsio from Ars Technica. How we summarize →